Next Article in Journal
The Antistaphylococcal Activity of Citropin 1.1 and Temporin A against Planktonic Cells and Biofilms Formed by Isolates from Patients with Atopic Dermatitis: An Assessment of Their Potential to Induce Microbial Resistance Compared to Conventional Antimicrobials
Next Article in Special Issue
Aptamers: A New Technological Platform in Cancer Immunotherapy
Previous Article in Journal
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future
Open AccessArticle

Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer

1
Radiobiology Unit, Belgian Nuclear Research Centre (SCK•CEN), 2400 Mol, Belgium
2
Cyclotron Research Centre, University of Liège, 4000 Liège, Belgium
3
NeoVentures Biotechnology Inc., London, N6A 1A1 ON, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Alfredo Berzal-Herranz
Pharmaceuticals 2016, 9(2), 29; https://doi.org/10.3390/ph9020029
Received: 20 February 2016 / Revised: 9 May 2016 / Accepted: 10 May 2016 / Published: 19 May 2016
(This article belongs to the Special Issue Aptamers: Biomedical Interest and Applications)
Aptamers provide a potential source of alternative targeting molecules for existing antibody diagnostics and therapeutics. In this work, we selected novel DNA aptamers targeting the HER2 receptor by an adherent whole-cell SELEX approach. Individual aptamers were identified by next generation sequencing and bioinformatics analysis. Two aptamers, HeA2_1 and HeA2_3, were shown to bind the HER2 protein with affinities in the nanomolar range. In addition, both aptamers were able to bind with high specificity to HER2-overexpressing cells and HER2-positive tumor tissue samples. Furthermore, we demonstrated that aptamer HeA2_3 is being internalized into cancer cells and has an inhibitory effect on cancer cell growth and viability. In the end, we selected novel DNA aptamers with great potential for the diagnosis and possible treatment of HER2-positive cancer. View Full-Text
Keywords: aptamer; DNA; HER2; diagnosis; therapeutics; cancer aptamer; DNA; HER2; diagnosis; therapeutics; cancer
Show Figures

Figure 1

MDPI and ACS Style

Gijs, M.; Penner, G.; Blackler, G.B.; Impens, N.R.; Baatout, S.; Luxen, A.; Aerts, A.M. Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer. Pharmaceuticals 2016, 9, 29.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop